Aclaris Therapeutics (NASDAQ:ACRS) Sets New 12-Month High at $18.63

Aclaris Therapeutics, Inc. (NASDAQ:ACRSGet Rating) shares reached a new 52-week high during trading on Wednesday . The stock traded as high as $18.63 and last traded at $18.63, with a volume of 641 shares trading hands. The stock had previously closed at $17.98.

Analysts Set New Price Targets

Several research firms recently commented on ACRS. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Aclaris Therapeutics in a research report on Monday, August 1st. BTIG Research initiated coverage on shares of Aclaris Therapeutics in a research report on Thursday, October 6th. They set a “buy” rating and a $32.00 price target on the stock. StockNews.com initiated coverage on shares of Aclaris Therapeutics in a research report on Wednesday, October 12th. They set a “sell” rating on the stock. Finally, SVB Leerink reissued an “outperform” rating on shares of Aclaris Therapeutics in a research report on Tuesday, November 8th. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $36.00.

Aclaris Therapeutics Trading Up 0.2 %

The company has a market capitalization of $1.20 billion, a price-to-earnings ratio of -13.95 and a beta of 0.55. The firm’s 50 day moving average price is $15.68 and its two-hundred day moving average price is $15.12.

Insider Transactions at Aclaris Therapeutics

In other news, insider Joseph Monahan sold 5,000 shares of the business’s stock in a transaction dated Monday, October 17th. The shares were sold at an average price of $15.98, for a total transaction of $79,900.00. Following the transaction, the insider now directly owns 101,386 shares in the company, valued at approximately $1,620,148.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, insider Joseph Monahan sold 5,000 shares of the business’s stock in a transaction dated Monday, October 17th. The shares were sold at an average price of $15.98, for a total transaction of $79,900.00. Following the transaction, the insider now directly owns 101,386 shares in the company, valued at approximately $1,620,148.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Andrew N. Schiff sold 7,700 shares of the business’s stock in a transaction dated Tuesday, October 4th. The stock was sold at an average price of $16.01, for a total transaction of $123,277.00. Following the transaction, the director now owns 626,755 shares in the company, valued at $10,034,347.55. The disclosure for this sale can be found here. Insiders have sold 99,639 shares of company stock worth $1,644,933 in the last ninety days. Insiders own 6.70% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of ACRS. Nisa Investment Advisors LLC acquired a new position in Aclaris Therapeutics in the 2nd quarter valued at about $26,000. Great West Life Assurance Co. Can acquired a new position in Aclaris Therapeutics in the 3rd quarter valued at about $31,000. UBS Group AG grew its stake in Aclaris Therapeutics by 41.4% in the 2nd quarter. UBS Group AG now owns 2,406 shares of the biotechnology company’s stock valued at $34,000 after buying an additional 704 shares during the last quarter. Cubist Systematic Strategies LLC grew its stake in Aclaris Therapeutics by 163.9% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 9,050 shares of the biotechnology company’s stock valued at $126,000 after buying an additional 5,621 shares during the last quarter. Finally, Amalgamated Bank bought a new stake in Aclaris Therapeutics in the 1st quarter valued at about $143,000. Institutional investors and hedge funds own 95.08% of the company’s stock.

About Aclaris Therapeutics

(Get Rating)

Aclaris Therapeutics, Inc operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases.

Featured Articles

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.